hydroxychloroquine has been researched along with Delayed Effects, Prenatal Exposure in 11 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 7.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "The use of hydroxychloroquine (HCQ) in pregnancy remains controversial." | 5.10 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. ( Amoura, Z; Costedoat-Chalumeau, N; Denjoy, I; Duhaut, P; Huong, DL; Lupoglazoff, JM; Piette, JC; Sebbough, D; Vauthier, D; Wechsler, B, 2003) |
| ", chloroquine and hydroxychloroquine, in pregnant patients with lupus who continued antimalarial drugs throughout pregnancy." | 5.08 | Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. ( Parke, A; West, B, 1996) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| "Hydroxychloroquine therapy during pregnancy is thought to be safe for foetuses." | 3.75 | Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. ( Flores-Guevara, R; Gold, F; Renaud, C; Renault, F; Richard, P; Vermersch, AI, 2009) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 3.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Knudsen, SS | 1 |
| Simard, JF | 1 |
| Knudsen, JS | 1 |
| Christensen, J | 1 |
| Laursen, TM | 1 |
| Deleuran, BW | 1 |
| Bech, BH | 1 |
| Renault, F | 1 |
| Flores-Guevara, R | 1 |
| Renaud, C | 1 |
| Richard, P | 1 |
| Vermersch, AI | 1 |
| Gold, F | 1 |
| Ingster-Moati, I | 1 |
| Albuisson, E | 1 |
| Izmirly, PM | 1 |
| Kim, MY | 1 |
| Llanos, C | 1 |
| Le, PU | 1 |
| Guerra, MM | 1 |
| Askanase, AD | 1 |
| Salmon, JE | 1 |
| Buyon, JP | 1 |
| Mulholland, CP | 1 |
| Pollock, TJ | 1 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Koren, G | 2 |
| Costedoat-Chalumeau, N | 1 |
| Amoura, Z | 1 |
| Duhaut, P | 1 |
| Huong, DL | 1 |
| Sebbough, D | 1 |
| Wechsler, B | 1 |
| Vauthier, D | 1 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Piette, JC | 1 |
| Cimaz, R | 1 |
| Brucato, A | 1 |
| Meregalli, E | 1 |
| Muscará, M | 1 |
| Sergi, P | 1 |
| Motta, M | 1 |
| Ciardelli, L | 1 |
| Marconi, M | 1 |
| Tincani, A | 1 |
| Gasparoni, A | 1 |
| Lojacono, A | 1 |
| Chirico, G | 1 |
| Parke, A | 1 |
| West, B | 1 |
| Klinger, G | 1 |
| Morad, Y | 1 |
| Westall, CA | 1 |
| Laskin, C | 1 |
| Spitzer, KA | 1 |
| Ito, S | 1 |
| Buncic, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
2 trials available for hydroxychloroquine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Topics: Antirheumatic Agents; Birth Weight; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydr | 2003 |
Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Topics: Antimalarials; Child, Preschool; Contraindications; Female; Fetus; Follow-Up Studies; Hearing Disord | 1996 |
8 other studies available for hydroxychloroquine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - A Danish population-based study.
Topics: Academic Performance; Adolescent; Adolescent Development; Adult; Child; Child Development; Denmark; | 2021 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Electroretinography; Evoked Potentials, Visual; Fe | 2009 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Electroretinography; Evoked Potentials, Visual; Female; Humans; Hydroxychloroquine; Infant; Infant, | 2010 |
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.
Topics: Antirheumatic Agents; Autoantibodies; Autoantigens; Case-Control Studies; Female; Heart Diseases; Hu | 2010 |
The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine.
Topics: Anterior Eye Segment; Antirheumatic Agents; Arthritis, Rheumatoid; Corneal Opacity; Enzyme Inhibitor | 2011 |
Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al.
Topics: Autoimmune Diseases; Breast Feeding; Child, Preschool; Electroretinography; Female; Humans; Hydroxyc | 2004 |
Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents.
Topics: Autoimmune Diseases; Azathioprine; Cyclosporine; Female; Humans; Hydroxychloroquine; Immune System; | 2007 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infa | 2001 |